medigraphic.com
ISSN 0016-3813 (Impreso)

2009, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2009; 145 (6)


Coxib: una alternativa terapéutica factible en pacientes con intolerancia o hipersensibilidad al ácido acetilsalicílico, antiinflamatorios no esteroideos y paracetamol

Ramos-Bello D, Ramos-Niembro F

Idioma: Español
Referencias bibliográficas: 201
Paginas: 505-515
Archivo PDF: 108.56 Kb.


RESUMEN

El ácido acetilsalicílico (AAS) o aspirina, los antiinflamatorios no esteroideos (AINE) y el acetaminofén o paracetamol son los medicamentos más utilizados a nivel mundial para el manejo del dolor, inflamación y fiebre que acompañan a una gran variedad de padecimientos agudos y crónicos. Pese a sus propiedades analgésicas, antiinflamatorias y antipiréticas, se han asociado a una gama de efectos adversos, los cuales están mediados fundamentalmente por los mismos mecanismos que logran el control del dolor, la inflamación y la fiebre. Un problema relativamente frecuente con el empleo de AINE o AAS o paracetamol es el desarrollo de intolerancia y diversas reacciones de hipersensibilidad, situación para la cual se han propuesto diversas alternativas, entre ellas el empleo de los inhibidores específicos de la ciclooxigenasa 2, modalidad terapéutica analizada en el presente trabajo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abramson S. Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1991;3:336-340.

  2. Vane JR, Bootting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S.

  3. Brooks P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:9S-13S.

  4. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990;121:(Suppl IV):12-23.

  5. Ramos-Niembro F. Antiinflamatorios no esteroideos (Parte I). Del ácido acetilsalicílico (1899) a los inhibidores selectivos de COX2 (1999). Rev Mex Reumatol 2000:15:142-159.

  6. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001;110(1A):4S-7S.

  7. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3-27.

  8. Bränd Persson K, Strøm H. The Anatomical Therapeutic Chemical (ATC) classification and its use in the Nordic countries (document WHO/GPE/CAS/C/02.49). Meeting of Heads of WHO Collaborating Centres for the Classification of Diseases. Brisbane (Australia); 2002. Disponible en http://www.aihw.gov.au/international/who_hoc/hoc_02_papers/brisbane49.doc

  9. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. Disponible en http://www.whocc.no/atcddd/

  10. Gaciong Z. The real dimension of analgesic activity of aspirin. Thromb Res 2003;110:361-364.

  11. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008;21:331-337.

  12. Botting R. Antipyretic therapy. Front Biosci 2004;9:956-966.

  13. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

  14. Craven LL. Coronary thrombosis can be prevented. J Insur Med 1950;5:47-48.

  15. Craven LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 1950;4:95.

  16. Tamchés E, Buclin T, Hugli O, Decosterd I, Blanc C, Mouhsine E, et al. Acute pain in adults admitted to the emergency room: development and implementation of abbreviated guidelines. Swiss Med Wkly 2007;137:223-227.

  17. Langford RM. Pain management today - what have we learned? Clin Rheumatol 2006;25 Suppl 1:S2-S8.

  18. Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol 2008;8:11.

  19. Martelletti P, Farinelli I, Steiner TJ. Working Group for Specialist Education, WHO’s Global Campaign to Reduce the Burden of Headache Worldwide (Lifting The Burden). Acute migraine in the Emergency Department: extending European principles of management. Intern Emerg Med 2008;3 Suppl 1:S17-S24.

  20. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000.

  21. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162.

  22. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2005;(2):CD004137.

  23. French L. Dysmenorrhea. Am Fam Physician 2005;71:285-291.

  24. Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev 2003;(4):CD001751.

  25. Pyati S, Gan TJ. Perioperative pain management. CNS Drugs 2007;21:185-211.

  26. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg 2005;101(5 Suppl):S5-S22.

  27. World Health Organization. Cancer pain relief, with a guide to opioid availability. 2nd edition. Geneva, Switzerland: World Health Organization; 1996.

  28. Potter MB. NSAIDs alone or with opioids as therapy for cancer pain. Am Fam Phys 2005;72:436-437.

  29. Wilson JT, Brown RD, Kearns GL, Eichler VF, Johnson VA, Bertrand KM, et al. Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr 1991;119:803-811.

  30. Walson PD, Galletta G, Braden NJ, Alexander L. Ibuprofen, acetaminophen, and placebo treatment of febrile children. Clin Pharmacol Ther 1989;46:9-17.

  31. Hay AD, Costelloe C, Redmond NM, Montgomery AA, Fletcher M, Hollinghurst S, et al. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. BMJ 2008;337:a1302.

  32. Meremikwu M, Oyo-Ita A. Paracetamol for treating fever in children. Cochrane Database Syst Rev 2002;(2):CD003676.

  33. Wilson JT, Brown RD, Kearns GL, Eichler VF, Johnson VA, Bertrand KM, et al. Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr 1991;119:803-811.

  34. Walson PD, Galletta G, Braden NJ, Alexander L. Ibuprofen, acetaminophen, and placebo treatment of febrile children. Clin Pharmacol Ther 1989;46:9-17.

  35. Hämäläinen ML. Migraine in children and adolescents: a guide to drug treatment. CNS Drugs 2006;20:813-820.

  36. Stockler M, Vardy J, Pillai A, Ward D. Acetaminophen (Paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-3394.

  37. Barden J, Edwards J, Moore A, McQuay H. Single dose oral paracetamol (acetaminophen) for postoperative pain. Cochrane Database Syst Rev 2004;(1):CD004602.

  38. Weil K, Hooper L, Afzal Z, Esposito M, Worthington HV, van Wijk AJ, et al. Paracetamol for pain relief after surgical removal of lower wisdom teeth. Cochrane Database Syst Rev 2007;(3):CD004487.

  39. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985;12:13-20.

  40. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985;12:347-353.

  41. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985;12:562-567.

  42. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985;12:785-790.

  43. Velo GP, Milanino R. Nongastrointestinal adverse reactions to NSAID. J Rheumatol 1990;17:(Suppl 20):42-45.

  44. Ramos Niembro F. Antiinflamatorios no esteroideos (Parte II). Del ácido acetilsalicílico (1899) a los inhibidores selectivos de COX2 (1999). Rev Mex Reumatol 2000:15:170-182.

  45. Gallelli L, Colosimo M, Pirritano D, Ferraro M, De Fazio S, Marigliano NM, et al. Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs. Clin Drug Invest 2007;27:115-122.

  46. Committee on the Safety of Medicines. CSM update: nonsteroidal antiinflammatory drugs and serious gastrointestinal adverse reactions-1. BMJ 1986;292:614.

  47. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal antiinflammatory drugs. Am J Med 1998;105(1B):20S-30S.

  48. Wolfe M, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899.

  49. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. J Rheumatol 1998;25 (Suppl 51):8-16.

  50. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.

  51. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.

  52. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895.

  53. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.

  54. Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2007;23:617-624.

  55. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756-1764.

  56. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24:491-505.

  57. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.

  58. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004;292:3017-3023.

  59. Settipane GA. Aspirin and allergic diseases: a review. Am J Med 1983;74(6A): 102-109.

  60. Strom BL, Carson JL, Lee Morse M, West SL, Soper KA. The effect of indication of hypersensitivity ractions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum 1987;30:1142-1148.

  61. Giraldo B, Blumenthal MN, Spink WW. Aspirin intolerance and asthma. A clinical and immunological study. Ann Intern Med 1969;71:479-496.

  62. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983;71:574-579.

  63. Mathison DA, Lumry WR, Stevenson DD. Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitation. J Allerg Clin Immmunol 1982;69:135 (abstract).

  64. Blanca M, Pérez E, García JJ, Miranda A, Terrados S, Vega JM, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989;62:295-298.

  65. Phills JA, Perelmutter L. IgE mediated and non-IgE mediated allergic-type reactions to aspirin. Acta Allergol 1974;29:474-490.

  66. Krilis S, Gregson RP, Basten A, Baldo BA. Investigation of the possible involvement of IgE anti-salicyloyl antibodies in patients with urticaria. Int Arch Allergy Appl Immunol 1981;64:293-301.

  67. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirinsensitive patients. BMJ 1975:67-69.

  68. Mathison DA, Stevenson DD. Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges. J Allergy Clin Immunol 1979;64(6 pt 2):669-674.

  69. Schmitz-Schumann M, Menz G, Schäufele A, von Felten A, Matthys H, de Souza V, et al. Evidence of PAF release and platelet activation in analgesicsasthma-syndrome. Agents Actions 1987;21 Suppl:215-223.

  70. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.

  71. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161(2 Pt 1):391-398.

  72. Penrose JF, Baldasaro MH. Leukotriene C4 synthase: a candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc 1999;20:353-360.

  73. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-1600.

  74. Kumlin M, Dahlén B, Björck T, Zetterström O, Granström E, Dahlén SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.

  75. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-399.

  76. Harrington LS, Lucas R, McMaster SK, Moreno L, Scadding G, Warner TD, et al. COX1, and not COX2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J 2008;22:4005-4010.

  77. Micheletto C, Visconti M, Tognella S, Trevisan F, Dal Negro RW. Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders. Eur Ann Allergy Clin Immunol 2007;39:162-166.

  78. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, et al. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis 1992;146:1531-1534.

  79. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143(5 Pt 1):1025-1029.

  80. Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. Ann Pharmacother 2007;41:1191-1200.

  81. Enrique E, Cisteró-Bahíma A, San Miguel-Moncín MM, Alonso R. Rofecoxib should be tried in NSAID hypersensitivity. Allergy 2000;55:1090.

  82. Garrido-Serrano P, Poza-Güedes P, Vives-Conesa R, Rivas-Plata Sierra C, González-Pérez R, Rosado-Ingelmo A, et al. Rofecoxib: ¿fármaco alternativo en pacientes con intolerancia a AINEs (IA)? Alergol Inmunol Clin 2000;15 (Extraordinario Núm. 3):53.

  83. Karakaya G, Kalyoncu AF. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunopathol 2000;28:319-321.

  84. Madera J, Díez B. Tolerancia a rofecoxib en intolerantes a AINEs. Alergol Inmunol Clin. 2000;15 (Extraordinario Núm. 3):57.

  85. Stevenson DD, Simon RA, Christiansen SC. Lack of crossreactivity between selective COX2 inhibitors and aspirin (ASA) in ASA-sensitive asthmatics. J Allerg Clin Immunol 2000;105;1(Part 2):S273. (Abstract).

  86. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000;106:1201.

  87. Asero R. Tolerability of rofecoxib. Allergy 2001;56:916-917.

  88. Berges-Gimeno MP, Camacho-Garrido E, García-Rodríguez RM, Alfaya T, Martín García C, Hinojosa M. Rofecoxib safe in NSAID hypersensitivity. Allergy 2001;56:1017-1018.

  89. Dahlén B, Szczeklik A, Murray JJ. Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001;344:142.

  90. Espínola S, Mora D, Brizuela M. Intolerancia al rofecoxib en pacientes intolerantes a AINE Arch Alergia Inmunol Clin 2001; 32:121-123.

  91. Hinrichs R, Ritzkowsky A, Hunzelmann N, Krieg T, Scharffetter-Kochanek K. Rofecoxib as an alternative in aspirin hypersensitivity. Allergy 2001;56:789.

  92. Marks F, Harrell K, Fischer R. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J 2001;94:256-257.

  93. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Pérez CR. Tolerability to new COX2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-204.

  94. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.

  95. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-225.

  96. Vaghi A, De Bernardi G, Grassi N, Capato S, Cicchitto G, Sestini P, et al. Tolerance of two COX2 inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics. Eur Respir J 2001;18:428s.

  97. Zollner TM, Ahlbach S, Kaufmann R, Boehncke WH. Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents. Dtsch Med Wochenschr 2001;126:386-388.

  98. Dama AR, Liccardi G, Lobefalo G, Bonadonna P, Schiappoli M, Crivellano M, et al. Celecoxib a new selective COX2 inhibitor is a safe alternative drug in highly intolerant NSAIDs patients. J Allergy Clin Immunol 2002;109:S141.

  99. Fernández-Meléndez S, Miranda A, Carmona MJ, Díaz J, Barceló JM, Vega JM, et al. Tolerance to rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). J Allergy Clin Immunol 2002;109:S140.

  100. García-Rodríguez RM, Hinojosa M, Camacho-Garrido E, Berges Gimeno P, Martín-García C. Celecoxib, safe in NSAID intolerance. Allergy 2002;57:1085-1086.

  101. Leong KP, Tang CY, Thong B, Tan HH. The safety of rofecoxib in patients with NSAIDs-induced urticaria and angioedema. J Allergy Clin Immunol 2000;109:S140.

  102. Martín-García C, Hinojosa M, Berges P, Camacho E, García-Rodríguez R, Alfaya T, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirinsensitive asthma. Chest 2002;121:1812-1817.

  103. Nettis E, Di PR, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331-334.

  104. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32:397-340.

  105. Ortega-Rodríguez N, Torres MJ, Almeida L, Navarro L, Carrillo T. Tolerancia a los nuevos inhibidores de la COX2 en el asma y urticaria angioedema con idiosincrasia a AINEs. Alergol Immunol Clin 2002;17 (Extraordinario 2):30-34.

  106. Quiralte J, Sáenz de San Pedro B, Florido JJ. Safety of selective cyclooxygenase- 2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002;89:63-66.

  107. Valero A, Baltasar M, Enrique E, Pau L, Dordal MT, Cisteró A, et al. NSAIDsensitive patients tolerate rofecoxib. Allergy 2002;57:1214-1215.

  108. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002;46:2201-2206.

  109. Ahlbach S, Usadel KH, Kaufmann R, Boehncke WH. The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs] Med Klin 2003;98:242-244.

  110. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Shelle J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-1121.

  111. Kruse R, Ruzicka T, Grewe M. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity. Acta Derm Venereol 2003;83:183-185.

  112. Martín-García C, Hinojosa M, Berges P, Camacho E, García-Rodríguez R, Alfaya T. Celecoxib, a highly selective COX2 inhibitor, is safe in aspirininduced asthma patients. J Invest Allergol Clin Immunol 2003;13:20-25.

  113. Montalvo S, Dávila I, Laffond E. Tolerancia de rofecoxib en pacientes con reacciones a AINES. Alergol Inmunol Clin 2003;18:214-216.

  114. Muñoz-Bellido FJ, Terrón M, León A. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 2003;58:1072-1075.

  115. Passero M, Chowdhry S. Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma. Chest. 2003;123:2155-2156.

  116. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal antiinflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol. 2003;132:82-86.

  117. Rodríguez M, Enrique E, Castello JV, de Mateo JA, Roca B, Malek T. Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge. Ann Allergy Asthma Immunol 2003;91:589.

  118. Valero A, Enrique E, Baltasar M, Cisteró A, Martí E, Picado C, et al. Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions. Med Clin 2003;121:695-696.

  119. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577-1582.

  120. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004;41:67-75.

  121. Giamarchi D, Escamilla R. Carme S, Krempf M. Selective COX2 inhibitors: a safety alternative for patients with intoerance to non-steroidal anti-inflammatory drugs (NSAIDs). J Allergy Clin Immunol 2004;113:S180.

  122. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, et al. Partial safety of the new COX2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy. 2004;59:1133-1134.

  123. Quiralte J, Delgado J, Sáenz de San Pedro B, López-Pascual E, Nieto MA, Ortega N, et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004;93:360-364.

  124. Senna G, Biló MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol. 2004;36:215-218.

  125. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004;93:339-344.

  126. Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Dtsch Med Wochenschr 2005;130:2249-2252.

  127. Çelik G, Erkekol FO, Bavbek S, Dursun B, Misirligil Z. Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 2005;95:33-37.

  128. Espínola S, Repta S, Brizuela M. Tolerance to celecoxib in patients with intoleance to NASIDs. An Fac Cienc Med 2005;8:83-87.

  129. Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D’Amato M, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2005;15:249-253.

  130. Liccardi G, Salzillo A, Piccolo A, Senna G, Piscitelli E, D’Amato M, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 2005;37:50-53.

  131. Malhiero D, Cadinha S, Rodríguez J, Castel-Branco MG. Hipersensibilidad a AINEs: O papel dos fármacos inibidores da COX2 como fármacos alternativos. Rev Port Inmunoalergol 2005;13:243-250.

  132. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal antiinflammatory drugs. Ann Allergy Asthma Immunol 2005;94:8-11.

  133. Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005;95:438-442.

  134. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol. 2005;94:34-38.

  135. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal antiinflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154-158.

  136. Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005;137:145-150.

  137. Bavbek S, Celik G, Pasaoglu G, Misirligil Z. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. J Investig Allergol Clin Immunol 2006;16:57-62.

  138. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:105-109.

  139. Micheletto C, Tognella S, Guerriero M, Dal Negro R. Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. Eur Ann Allergy Clin Immunol 2006;38:10-14.

  140. Nahar IK, Muqim AT, Al-Qhouti BI, Al-Herz AA, Shehab DK, Uppal SS, et al. The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity. Saudi Med J 2006;27:119-120.

  141. Roll A, Wüthrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber BK. Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly 2006;136:684-690.

  142. Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A. Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 2006;117:1189-1191.

  143. Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. Allergol Immunopathol 2007;35:126-129.

  144. Asero R. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clin Exp Dermatol 2007;32:661-663.

  145. Muratore L, Ventura M, Calogiuri G, Calcagnile F, Quarta E, Muratore M. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2007;98:168-171.

  146. Sánchez-Borges M, Capriles Hulett A, Caballero Fonseca F. Cutaneous Hypersensitivity reactions to Inhibitors of cyclooxygenase-2. Results from 307 oral provocation tests and review of the literature. Allergy Clin Immunol Int 2007;19:44-49.

  147. Viola M, F, Caruso C, Valluzzi R, Romano A. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007;143:103-108.

  148. Celikel S, Isik SR, Karakaya G, Kalyoncu AF. Tolerability of lumiracoxib in patients with analgesic intolerance. J Invest Allergol Clin Immunol 2008;18:318-319.

  149. Colanardi MC, Nettis E, Traetta P, Delle Donne P, Ferrannini A, Vacca A. Parecoxib as an alternative in COX2 hypersensitivity. Int J Immunopathol Pharmacol 2008;21:233-235.

  150. Colanardi MC, Nettis E, Traetta P, Daprile C, Fitto C, Aloia AM, et al. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema. Ann Allergy Asthma Immunol 2008;100:82-85.

  151. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Safety of etoricoxib in patients with reactions to NSAIDs. J Invest Allergol Clin Immunol 2008;18:163-167.

  152. Vázquez-Cortés L, Vázquez-Fuentes L, Rodríguez-Álvarez M, Rincón-de Arellano R, Martínez-Cócera C. Tolerancia a celecoxib y meloxicam en pacientes con intolerancia a analgésicos no esteroideos. An Med Intern 2008;25:4;163-167.

  153. Hirschberg GV. Anaphylactoid reaction to aspirin (1902). Allergy Proc 1990;11:249-250.

  154. Widal MF, Abrami, P, Lenmoyez, J. Anaphylaxie et idiosyncrasie. Press Medicale 1922;30:189-192.

  155. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:875-883.

  156. Vanselow NA, Smith JR. Bronchial asthma induced by indomethacin. Ann Intern Med 1967;66:568-572.

  157. Hawkey CJ. COX2 inhibitors. Lancet 1999;353:307-314.

  158. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-593.

  159. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24:491-505.

  160. Domingo MV, Marchuet MJ, Culla MT, Joanpere RS, Guadaño EM. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2006;16:364-366.

  161. Quaratino D, Romano A, Papa G, Di Fonso M, Giuffreda F, D’Ambrosio FP, et al. Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;79:47-50.

  162. Confino-Cohen R, Goldberg A. Safe full-dose one-step nabumetone challenge in patients with nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Proc 2003;24:281-284.

  163. Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 2003;35:393-396.

  164. Senna GE, Passalacqua G, Andri G, Dama AR, Albano M, Fregonese L, et al. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Saf 1996;14:94-103.

  165. Prieto A, De Barrio M, Martín E, Fernández-Bohórquez M, de Castro FJ, Ruiz FJ, et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. J Allergy Clin Immunol 2007;119:960-964.

  166. Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung KA, Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 2004;64:2315-2343.

  167. Dahlén SE, Malmstrom K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.

  168. Dahlén B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-1194.

  169. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Ann Allergy Asthma Immunol 2006;97:688-693.

  170. Weberschock TB, Müller SM, Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature Arch Dermatol Res 2007;299:169-175.

  171. Downing A, Jacobsen J, Sorensen HT, McLaughlin JK, Johnsen SP. Risk of hospitalization for angio-oedema among users of newer COX2 selective inhibitors and other nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 2006;62:496-501.

  172. Grob M, Scheidegger P, Wüthrich B. Allergic skin reaction to celecoxib. Dermatology 2000;201:383.

  173. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001;87:72-73.

  174. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase- 2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 2001;345:1856.

  175. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 2001;28:2553-2554.

  176. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX2 inhibitors. J Allergy Clin Immunol 2002;109:370.

  177. Grob M, Pichler WJ, Wüthrich B. Anaphylaxis to celecoxib. Allergy 2002;57:264-265.

  178. Kumar NP, Wild G, Ramasamy KA, Snape J. Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib. Postgrad Med J 2002;78:439-440.

  179. Jordan KM, Edwards CJ, Arden NK. Allergic vasculitis associated with celecoxib. Rheumatology 2002;41:1453-1455.

  180. Schneider F, Meziani F, Chartier C, Alt M, Jaeger A. Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-853.

  181. Skowron F, Berard F, Bernard N, Balme B, Perrot H. Cutaneous vasculitis related to celecoxib. Dermatology 2002;204:305.

  182. Daugherty KK, Gora-Harper ML. Idiopathic paresthesia reaction associated with rofecoxib. Ann Pharmacother 2002;36:264-266.

  183. Fradet G, Robin-Le Nechet A, Huguenin H, Chiffoleau A. Syndrome d’hypersensibilité au celecoxib. Ann Med Intern 2003;154:181-182.

  184. Lillicrap MS, Merry P. Cutaneous vasculitis associated with rofecoxib. Rheumatology 2003;42:1267-1268.

  185. Schuster C, Wüthrich B. Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence? Allergy 2003;58:1072.

  186. Bagán JV, Thongprasom K, Scully C. Adverse oral reactions associated with the COX2 inhibitor rofecoxib. Oral Dis 2004;10:401-403.

  187. Abu-Shraie NA, Alfadley AA. Lichenoid drug eruption probably associated with rofecoxib. Ann Pharmacother 2004;38:795-798.

  188. Marshall LL. Angioedema associated with aspirin and rofecoxib. Ann Pharmacother 2005;39:944-948.

  189. Jacob S, Rajabally YA. Intracranial hypertension induced by rofecoxib. Headache 2005;45:75-76.

  190. Talhari C, Lauceviciute I, Enderlein E, Ruzicka T, Homey B. COX2- selective inhibitor valdecoxib induces severe allergic skin reactions. J Allergy Clin Immunol 2005;115:1089-1090.

  191. Simon RA, Stevenson DD. Cross-reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors. Ann Allergy Asthma Immunol 2005;94:8-11

  192. Looney Y, O’Shea A, O’Dwyer R. Severe bronchospasm after parenteral parecoxib: cyclooxygenase-2 inhibitors: not the answer yet. Anesthesiology 2005;102:473-475.

  193. Fontaine C, Bousquet PJ, Demoly P. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol 2005;115:633-634.

  194. Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA. Serious skin reactions and selective COX2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006;29:687-696.

  195. Baldassarre S, Schandene L, Choufani G, Michils A. Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol 2006;117:215-217.

  196. Wyplosz B, Vautier S, Lillo-Le Louët A, Capron L. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. Br J Clin Pharmacol 2006;61:474.

  197. Koschel D, Cardoso C, Leucht V, Hoffken G. Asthmatic reaction induced by Etoricoxib in a patient with aspirin-sensitive asthma. Allergy 2008;63:1093-1094.

  198. Muñoz-Cano R, Bartra J, Vennera MC, Valero A, Picado C. Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma. J Invest Allergol Clin Immunol 2009;19:75-76.

  199. Chamberlin KW, Silverman AR. Celecoxib-associated anaphylaxis. Ann Pharmacother 2009;43:777-781.

  200. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-1237.

  201. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004;171:1027-1028.




2020     |     www.medigraphic.com